Anti-CD94 antibodies and methods of use thereof

NZ837138APending Publication Date: 2026-09-25DREN BIO MANAGEMENT INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ837138
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-07
Filing Date
2021-09-29
Publication Date
2026-09-25

Smart Images

  • Figure 1_ABST
    Figure 1_ABST
Patent Text Reader

Abstract

The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.
Need to check novelty before this filing date? Find Prior Art